Back to Newsroom
Back to Newsroom

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NTNX, APYX and INVVY

Wednesday, 22 May 2019 06:30 PM

The Klein Law Firm

Topic:
5

NEW YORK, NY / ACCESSWIRE / May 22, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Nutanix, Inc. (NASDAQGS: NTNX)

Class Period: Class A shares purchased between March 2, 2018 and February 28, 2019
Lead Plaintiff Deadline: May 28, 2019

The complaint concerns whether the Company and its executives violated federal securities laws by making false and/or misleading statements about its investments in growth and its maintenance of high profit margins.

On February 28, 2019, Nutanix announced its second quarter fiscal 2019 results and reported third quarter guidance that was below analysts' expectations. Management acknowledged that "inadequate marketing spend for pipeline generation and slower than expected sales hiring" were the reasons for the weak guidance. On this news, Nutanix's share price fell from $50.09 per share on February 28, 2019 to a closing price of $33.70 on March 1, 2019.

Get additional information about the NTNX lawsuit: http://www.kleinstocklaw.com/pslra-1/nutanix-inc-loss-submission-form?id=1629&from=1

Apyx Medical Corporation (NASDAQ: APYX)

Class Period: August 1, 2018 to April 1, 2019
Lead Plaintiff Deadline: June 17, 2019

Apyx Medical Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint; (2) as a result, the clinical study did not support the Company's application for regulatory clearance; (3) as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the APYX lawsuit: http://www.kleinstocklaw.com/pslra-1/apyx-medical-corporation-loss-submission-form?id=1629&from=1

Indivior PLC (OTC Pink: INVVY)

Class Period: March 10, 2015 to April 9, 2019
Lead Plaintiff Deadline: June 24, 2019

The complaint alleges that during the class period Indivior PLC made materially false and/or misleading statements and/or failed to disclose that: (1) Indivior and its executives engaged in an illicit nationwide scheme to increase prescriptions of Suboxone Film; (2) Indivior illegally obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers and health care benefit programs; (3) as a result of the aforementioned misconduct, Indivior would face felony charges; and (4) due to the foregoing, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Get additional information about the INVVY lawsuit: http://www.kleinstocklaw.com/pslra-1/indivior-plc-loss-submission-form?id=1629&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

Topic:
5
Back to newsroom
Back to Newsroom
Share by: